Illumina founded Grail and spun it off in 2016, but re-acquired it in 2021 for $7.1 billion to enter the cancer early-detection market, before first securing EU regulatory approval.

BRUSSELS, April 26 (Reuters) - Chinese-founded fast-fashion company Shein will have to comply with tough new EU online content rules after its user numbers soared above a key benchmark ...

BRUSSELS, April 12 (Reuters) - U.S. gene sequencing company Illumina's plan to divest cancer diagnostic test maker Grail received the green light from EU antitrust regulators on Friday after ...

BRUSSELS, April 12 (Reuters) - U.S. gene sequencing company Illumina's plan to divest cancer diagnostic test maker Grail received the green light from EU antitrust regulators on Friday after having ...

BRUSSELS (Reuters) -U.S. gene sequencing company Illumina's plan to divest cancer diagnostic test maker Grail received the green light from EU antitrust regulators on Friday after having blocked the ...

BRUSSELS (Reuters) -U.S. gene sequencing company Illumina (NASDAQ:ILMN)'s plan to divest cancer diagnostic test maker Grail received the green light from EU antitrust regulators on Friday after ...